Olema Oncology to Participate at Upcoming Investor Conferences
February 21 2023 - 4:30PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that the Company will present
at the following upcoming investor conferences:
- Sean Bohen, M.D., Ph.D., President
and Chief Executive Officer, will participate in a fireside chat at
Citi’s 2023 Virtual Oncology Leadership Summit on
Thursday, February 23, 2023, at 12:00 p.m. ET.
- Shane Kovacs, Chief Operating and
Financial Officer, will participate in the Breast and Lung Cancer
Corporate Panel at Cowen’s 43rd
Annual Healthcare Conference on Tuesday, March 7,
2023, at 10:30 a.m. ET in Boston, MA.
A live webcast of these events will be available under the News
& Events section of Olema’s Investor Relations website at
www.olema.com and will be archived for at least 30 days.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, OP-1250, is a proprietary,
orally-available small molecule with dual activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated both as a
single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been
granted FDA Fast Track designation. Olema is headquartered in San
Francisco and has operations in Cambridge, Massachusetts.
IR Contact:Courtney Dugan, Vice President, Investor
Relations and Communications ir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024